BTIG analyst Justin Zelin assumed coverage of Verastem with a Buy rating and $27 price target. Verastem is a clinical stage small-molecule oncology company focused on developing treatments for various solid tumors, the analyst tells investors in a research note. The firm says The company’s lead asset is avutometinib, a dual RAF/MEK inhibitor, which together with the drug defactinib has the potential to be filed under accelerated approval and be a new standard of care in low-grade serous ovarian cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VSTM:
- Verastem price target lowered to $34 from $39 at Truist
- Verastem files $300M mixed securities shelf
- Verastem reports Q3 adjusted EPS (71c), consensus (84c)
- Verastem announces results from avutometinib, defactinib trial at IGCS 2023
- Verastem announces initial results of RAMP 203 trial of avutometinib, LUMAKRAS
